^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TQB2102

    i
    Other names: TQB2102
    Associations

    News

    Trials
    Company:
    Sino Biopharm
    Drug class:
    Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    5d
    TQB2102-II-03: A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality (clinicaltrials.gov)
    P2, N=270, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | N=190 --> 270
    Enrollment change • Metastases
    |
    Andewei (benmelstobart) • TQB2102
    30d
    TQB2102-II-02: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (clinicaltrials.gov)
    P2, N=42, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    TQB2102
    2ms
    TQB2102-II-02: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (clinicaltrials.gov)
    P2, N=42, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Initiation date: Jul 2024 --> Nov 2024
    Trial initiation date • Metastases
    |
    TQB2102
    4ms
    A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=542, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P3 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    capecitabine • albumin-bound paclitaxel • TQB2102
    4ms
    TQB2102-II-03: A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality (clinicaltrials.gov)
    P2, N=190, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    TQB2102
    5ms
    A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=103, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    TQB2102
    5ms
    A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality (clinicaltrials.gov)
    P2, N=190, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
    New P2 trial • Metastases
    |
    TQB2102
    6ms
    The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (clinicaltrials.gov)
    P2, N=42, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
    New P2 trial • Metastases
    |
    TQB2102
    7ms
    A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=103, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    TQB2102
    10ms
    A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (clinicaltrials.gov)
    P2, N=104, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TQB2102
    11ms
    A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (clinicaltrials.gov)
    P2, N=104, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P2 trial
    |
    TQB2102
    1year
    A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=150, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    TQB2102
    1year
    A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=150, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    TQB2102
    almost2years
    Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers (clinicaltrials.gov)
    P1, N=71, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    TQB2102